Coeptis Therapeutics, Inc.
COEP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $82,849 | $28,913 | $28,795 | $10,586 |
| - Cash | $4,908 | $1,997 | $4,268 | $533 |
| + Debt | $100 | $1,333 | $2,040 | $1,399 |
| Enterprise Value | $78,041 | $28,249 | $26,567 | $11,452 |
| Revenue | $237 | $201 | $63 | $0 |
| % Growth | 18.3% | 219.2% | – | – |
| Gross Profit | $192 | $156 | $18 | -$260 |
| % Margin | 81% | 77.5% | 28.2% | – |
| EBITDA | -$2,530 | -$3,961 | -$3,044 | -$2,673 |
| % Margin | -1,065.7% | -1,973.9% | -4,841.7% | – |
| Net Income | -$159 | -$3,535 | -$3,058 | -$3,012 |
| % Margin | -67.1% | -1,761.3% | -4,863.3% | – |
| EPS Diluted | -0.58 | -0.95 | -0.99 | 4.09 |
| % Growth | 38.9% | 4% | -124.2% | – |
| Operating Cash Flow | -$2,152 | -$2,397 | -$2,366 | -$1,437 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$2,152 | -$2,397 | -$2,366 | -$1,437 |